| Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine J Fredsøe, AKI Rasmussen, AR Thomsen, P Mouritzen, S Høyer, M Borre, ... European Urology Focus 4 (6), 825-833, 2018 | 104 | 2018 |
| 68Ga-PSMA PET/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer S Klingenberg, MR Jochumsen, BP Ulhøi, J Fredsøe, KD Sørensen, ... Journal of Nuclear Medicine 62 (2), 214-220, 2021 | 72 | 2021 |
| DNA hairpins as temperature switches, thermometers and ionic detectors AT Jonstrup, J Fredsøe, AH Andersen Sensors 13 (5), 5937-5944, 2013 | 67 | 2013 |
| DNA Topoisomerases Maintain Promoters in a State Competent for Transcriptional Activation in Saccharomyces cerevisiae JM Pedersen, J Fredsoe, M Roedgaard, L Andreasen, K Mundbjerg, ... PLoS genetics 8 (12), e1003128, 2012 | 62 | 2012 |
| A five‐microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell‐free urine J Fredsøe, AKI Rasmussen, P Mouritzen, M Borre, T Ørntoft, KD Sørensen International Journal of Cancer 145 (9), 2558-2567, 2019 | 39 | 2019 |
| Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors LB Andersen, M Nørgaard, M Rasmussen, J Fredsøe, M Borre, BP Ulhøi, ... The Journal of pathology 255 (2), 155-165, 2021 | 37 | 2021 |
| Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients L Schmidt, J Fredsøe, H Kristensen, SH Strand, A Rasmussen, S Høyer, ... Annals of oncology 29 (9), 2003-2009, 2018 | 36 | 2018 |
| Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer MT Bjerre, SH Strand, M Nørgaard, H Kristensen, AKI Rasmussen, ... International journal of molecular sciences 20 (5), 1173, 2019 | 35 | 2019 |
| Profiling of circulating microRNAs in prostate cancer reveals diagnostic biomarker potential J Fredsøe, AKI Rasmussen, P Mouritzen, MT Bjerre, P Østergren, M Fode, ... Diagnostics 10 (4), 188, 2020 | 28 | 2020 |
| The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer EB Hansen, J Fredsøe, TLH Okholm, BP Ulhøi, S Klingenberg, JB Jensen, ... Genome Medicine 14 (1), 8, 2022 | 24 | 2022 |
| Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential MT Bjerre, M Nørgaard, OH Larsen, SØ Jensen, SH Strand, P Østergren, ... Cells 9 (6), 1362, 2020 | 23 | 2020 |
| Elevated miR-615-3p expression predicts adverse clinical outcome and promotes proliferation and migration of prostate cancer cells EB Laursen, J Fredsøe, L Schmidt, SH Strand, H Kristensen, ... The American Journal of Pathology 189 (12), 2377-2388, 2019 | 22 | 2019 |
| Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine J Fredsøe, AKI Rasmussen, EB Laursen, Y Cai, KA Howard, BG Pedersen, ... Clinical Chemistry 65 (4), 540-548, 2019 | 22 | 2019 |
| High-throughput and automated acoustic trapping of extracellular vesicles to identify microRNAs with diagnostic potential for prostate cancer A Ku, J Fredsøe, KD Sørensen, M Borre, M Evander, T Laurell, H Lilja, ... Frontiers in oncology 11, 631021, 2021 | 21 | 2021 |
| Top2 and Sgs1-Top3 act redundantly to ensure rDNA replication termination K Mundbjerg, SW Jørgensen, J Fredsøe, I Nielsen, JM Pedersen, ... PLoS Genetics 11 (12), e1005697, 2015 | 20 | 2015 |
| DNA Topoisomerases Are Required for Preinitiation Complex Assembly during GAL Gene Activation M Roedgaard, J Fredsoe, JM Pedersen, L Bjergbaek, AH Andersen PLoS One 10 (7), e0132739, 2015 | 19 | 2015 |
| Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling PV Salachan, M Rasmussen, J Fredsøe, B Ulhøi, M Borre, KD Sørensen Genome Medicine 14 (1), 9, 2022 | 18 | 2022 |
| Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer M Nørgaard, MT Bjerre, J Fredsøe, S Vang, JB Jensen, B De Laere, ... Clinical Chemistry 69 (4), 386-398, 2023 | 14 | 2023 |
| The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: a cluster randomized controlled trial J Fredsøe, J Koetsenruyter, P Vedsted, P Kirkegaard, M Væth, A Edwards, ... PLoS Medicine 17 (2), e1003033, 2020 | 10 | 2020 |
| A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer MB Ipsen, EMG Sørensen, EA Thomsen, S Weiss, J Haldrup, A Dalby, ... Oncogene 41 (37), 4271-4281, 2022 | 9 | 2022 |
Siri H. StrandResearch Engineer, Stanford UniversityVerified email at stanford.edu
